Adcock Ingram
Annual Report
Quarterly Results
Investor Relations
FDB
GES
News Room
 
Press Release

Ayrton Drug Manufacturing Limited (“Ayrton”) – Offer from Adcock Ingram Holdings Limited (“Adcock Ingram”), on behalf of its wholly-owned subsidiary, Adcock Ingram International (Proprietary) Limited (“Adcock Ingram International”), for at least 51% of the entire issued ordinary share capital of Ayrton.

Notice to Ayrton Shareholders

Adcock Ingram hereby notifies all shareholders of Ayrton (“Ayrton Shareholders”) that the general conditions in paragraph 1 of Part VIII of the offer document dated 3 February 2010 (“Offer Document”) and the suspensive conditions set out in paragraph 2 of Part VIII of the Offer Document have been fulfilled and/or waived by Adcock Ingram. The Offer is accordingly unconditional in all respects. 

The results of the Offer are as follows: Read details


 
 
 
 
 
 
 
 
  click to download ...
 


AYRTON'S SHARES OFFER

The Board of Directors of Ayrton Drug Manufacturing Limited (Ayrton) wishes to inform all Ayrton shareholders of the commencement of the Offer from Adcock Ingram Holdings (Pty) Ltd (Adcock) to acquire at least 51% of the entire issued shares of Ayrton.  The Offer is for cash settlement at a price of GH¢0.16 per share.  It starts on Monday 15th February and ends on Monday 29th March, 2010.

The offer documents would have been dispatched through the post to all shareholders on the register of Ayrton from 8th February, 2010.

The Board of Directors of Ayrton has given its approval of the Offer and recommends to shareholders to accept the offer and this is contained in the offer document.  All completed tender documents should reach First Atlantic Brokers Limited (FABL), Lead Managers and Sponsoring Brokers of the Offer for Adcock latest by 5:00pm on 29th March, 2010.

Further information or any queries on the Offer may be obtained from FIRST ATLANTIC BROKERS LIMITED (FABL). 

The following are contact persons at FABL:  Kofi  -  0243234234, Philip  -  0244610689, and Gerard    0208597766; Direct Line  -  021 679259.

 
   
 
APPROVAL OF ADCOCK INGRAMS HOLDINGS LIMITED OFFER STATEMENT

The Board of Directors of Ayrton Drug Manufacturing Limited wishes to state that it has given its approval upon receipt of the Offer Statement from Adcock Ingram Holdings Limited (South Africa’s largest OTC drugs Company) to acquire at least 51% of the entire issued Ordinary Share Capital of Ayrton Drug Manufacturing Limited. 
Read details of full merger by clicking ...
 

 

©2008.All rights Reserved.Ayrton Drug Manufacturing Limited